Federal Register Notice: FDA has determined the regulatory review period for Nulojix is 4,479 days for extending a patent which claims the human biological product. Nulojix is indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant and is used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids. To view this notice, click here.
